Weikang (603676.SH) subsidiary obtains drug clinical trial approval notice.

Smart financial APP news, Weixinkang (603676.SH) announced that recently, its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. ("Baiyi Pharmaceutical") received the "Notice of Approval for Drug Clinical Trial" for Amber Acyl Gelatin Injection issued by the National Medical Products Administration (NMPA).